Related Experiment Videos
Immunosuppression in organ transplantation
S C Jordan1, P Rosenthal, L Makowka
1Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA 90048.
Seminars in Pediatric Surgery
|November 1, 1993
Summary
New immunosuppressive drugs like FK-506 and RS-61443 are advancing allograft rejection treatment. Understanding immune mechanisms is crucial for developing future immunosuppression therapies to prevent graft loss.
Area of Science:
- Immunology
- Pharmacology
- Transplantation
Background:
- Allograft rejection remains a significant challenge in transplantation.
- Cyclosporine and OKT3 are established immunosuppressants.
- Advances in immunosuppressive agents are critical for improving transplant outcomes.
Purpose of the Study:
- To highlight recent advancements in immunosuppressive agents for allograft rejection.
- To emphasize the importance of understanding immunologic mechanisms in immunosuppression therapy.
Main Methods:
- Review of recent developments in immunosuppressive drug classes.
- Discussion of the role of immunologic mechanisms in allograft rejection.
Main Results:
- Newer immunophylin drugs (e.g., FK-506) and lymphocyte DNA synthesis inhibitors (e.g., RS-61443) show promise.
- These agents are poised to join existing therapies like cyclosporine and OKT3.
Conclusions:
- Immunosuppressive therapy has rapidly progressed due to new drug development.
- Integrating basic immunologic understanding is essential for future immunosuppressive agent development and application.